238 related articles for article (PubMed ID: 24325778)
1. Simvastatin and bezafibrate increase cholesterol efflux in men with type 2 diabetes.
Triolo M; Annema W; de Boer JF; Tietge UJ; Dullaart RP
Eur J Clin Invest; 2014; 44(3):240-8. PubMed ID: 24325778
[TBL] [Abstract][Full Text] [Related]
2. Simvastatin but not bezafibrate decreases plasma lipoprotein-associated phospholipase A₂ mass in type 2 diabetes mellitus: relevance of high sensitive C-reactive protein, lipoprotein profile and low-density lipoprotein (LDL) electronegativity.
Constantinides A; de Vries R; van Leeuwen JJ; Gautier T; van Pelt LJ; Tselepis AD; Lagrost L; Dullaart RP
Eur J Intern Med; 2012 Oct; 23(7):633-8. PubMed ID: 22902096
[TBL] [Abstract][Full Text] [Related]
3. Statin and fibrate combination does not additionally lower plasma cholesteryl ester transfer in type 2 diabetes mellitus.
de Vries R; Dikkeschei BD; Sluiter WJ; Dallinga-Thie GM; van Tol A; Dullaart RP
Clin Lab; 2012; 58(11-12):1231-9. PubMed ID: 23289194
[TBL] [Abstract][Full Text] [Related]
4. Plasma apolipoprotein M responses to statin and fibrate administration in type 2 diabetes mellitus.
Kappelle PJ; Ahnström J; Dikkeschei BD; de Vries R; Sluiter WJ; Wolffenbuttel BH; van Tol A; Nielsen LB; Dahlbäck B; Dullaart RP
Atherosclerosis; 2010 Nov; 213(1):247-50. PubMed ID: 20828695
[TBL] [Abstract][Full Text] [Related]
5. Serum paraoxonase-I activity is unaffected by short-term administration of simvastatin, bezafibrate, and their combination in type 2 diabetes mellitus.
Dullaart RP; de Vries R; Voorbij HA; Sluiter WJ; van Tol A
Eur J Clin Invest; 2009 Mar; 39(3):200-3. PubMed ID: 19260949
[TBL] [Abstract][Full Text] [Related]
6. Effect of niacin on high-density lipoprotein apolipoprotein A-I kinetics in statin-treated patients with type 2 diabetes mellitus.
Pang J; Chan DC; Hamilton SJ; Tenneti VS; Watts GF; Barrett PH
Arterioscler Thromb Vasc Biol; 2014 Feb; 34(2):427-32. PubMed ID: 24285582
[TBL] [Abstract][Full Text] [Related]
7. Reconstituted high-density lipoprotein increases plasma high-density lipoprotein anti-inflammatory properties and cholesterol efflux capacity in patients with type 2 diabetes.
Patel S; Drew BG; Nakhla S; Duffy SJ; Murphy AJ; Barter PJ; Rye KA; Chin-Dusting J; Hoang A; Sviridov D; Celermajer DS; Kingwell BA
J Am Coll Cardiol; 2009 Mar; 53(11):962-71. PubMed ID: 19281927
[TBL] [Abstract][Full Text] [Related]
8. Combined bezafibrate and simvastatin treatment for mixed hyperlipidaemia.
Kehely A; MacMahon M; Barbir M; Wray R; Hunt BJ; Prescott RJ; Thompson GR
QJM; 1995 Jun; 88(6):421-7. PubMed ID: 7648234
[TBL] [Abstract][Full Text] [Related]
9. Effects of bezafibrate and simvastatin on plasma lipoproteins in hypercholesterolemia resistant to hormone replacement therapy.
Ohmichi M; Ikegami H; Kurachi H; Node K; Morishige K; Nishio Y; Adachi K; Matumoto K; Hayakawa J; Tasaka K; Azuma C; Murata Y
Maturitas; 2001 May; 38(3):279-86. PubMed ID: 11358645
[TBL] [Abstract][Full Text] [Related]
10. Comparison of bezafibrate and simvastatin in the treatment of dyslipidaemia in patients with NIDDM.
Jeck T; Riesen WF; Keller U
Diabet Med; 1997 Jul; 14(7):564-70. PubMed ID: 9223394
[TBL] [Abstract][Full Text] [Related]
11. Pravastatin compared to bezafibrate in the treatment of dyslipidemia in insulin-treated patients with type 2 diabetes mellitus.
Rustemeijer C; Schouten JA; Voerman HJ; Hensgens HE; Donker AJ; Heine RJ
Diabetes Metab Res Rev; 2000; 16(2):82-7. PubMed ID: 10751747
[TBL] [Abstract][Full Text] [Related]
12. Impact of bezafibrate and atorvastatin on lipoprotein subclass in patients with type III hyperlipoproteinemia: result from a crossover study.
Kawashiri MA; Kobayashi J; Nohara A; Noguchi T; Tada H; Nakanishi C; Inazu A; Mabuchi H; Yamagishi M
Clin Chim Acta; 2011 May; 412(11-12):1068-75. PubMed ID: 21354122
[TBL] [Abstract][Full Text] [Related]
13. Bezafibrate and simvastatin combination therapy for diabetic dyslipidaemia: efficacy and safety.
Gavish D; Leibovitz E; Shapira I; Rubinstein A
J Intern Med; 2000 May; 247(5):563-9. PubMed ID: 10809995
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and tolerability of combined treatment with L-carnitine and simvastatin in lowering lipoprotein(a) serum levels in patients with type 2 diabetes mellitus.
Solfrizzi V; Capurso C; Colacicco AM; D'Introno A; Fontana C; Capurso SA; Torres F; Gadaleta AM; Koverech A; Capurso A; Panza F
Atherosclerosis; 2006 Oct; 188(2):455-61. PubMed ID: 16384561
[TBL] [Abstract][Full Text] [Related]
15. Age, abdominal obesity, and baseline high-sensitivity C-reactive protein are associated with low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B responses to ezetimibe/simvastatin and atorvastatin in patients with metabolic syndrome.
Robinson JG; Ballantyne CM; Hsueh WA; Rosen JB; Lin J; Shah AK; Tomassini JE; Lowe RS; Tershakovec AM
J Clin Lipidol; 2013; 7(4):292-303. PubMed ID: 23890516
[TBL] [Abstract][Full Text] [Related]
16. Bezafibrate and simvastatin (MK-733) in the treatment of primary hypercholesterolaemia.
Smith DH; Neutel JM; Jankelow D; Myburgh DP
S Afr Med J; 1990 May; 77(10):500-3. PubMed ID: 2188379
[TBL] [Abstract][Full Text] [Related]
17. Marked removal of bezafibrate-induced high-density lipoprotein-cholesterol by low-density lipoprotein apheresis.
Kawano M; Kuroda Y; Terao M; Yaginuma T; Kawakami M; Kanazawa Y
Clin Chim Acta; 2002 Apr; 318(1-2):91-5. PubMed ID: 11880117
[TBL] [Abstract][Full Text] [Related]
18. [Effectiveness, tolerance and safety of simvastatin in comparison with bezafibrate in treatment of hypercholesterolemia].
Lechleitner M; Sailer S; Irsigler H; Klein W; Patsch JR
Wien Med Wochenschr; 1995; 145(21):577-83. PubMed ID: 8560901
[TBL] [Abstract][Full Text] [Related]
19. Remarkable quantitative and qualitative differences in HDL after niacin or fenofibrate therapy in type 2 diabetic patients.
Masana L; Cabré A; Heras M; Amigó N; Correig X; Martínez-Hervás S; Real JT; Ascaso JF; Quesada H; Julve J; Palomer X; Vázquez-Carrera M; Girona J; Plana N; Blanco-Vaca F
Atherosclerosis; 2015 Feb; 238(2):213-9. PubMed ID: 25528430
[TBL] [Abstract][Full Text] [Related]
20. Macrophage cholesterol efflux to plasma and HDL in subjects with low and high homocysteine levels: a FIELD substudy.
Maranghi M; Hiukka A; Badeau R; Sundvall J; Jauhiainen M; Taskinen MR
Atherosclerosis; 2011 Nov; 219(1):259-65. PubMed ID: 21696738
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
